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Monocytes/macrophages are an influential component of the glioma microenvironment. However, understanding
their diversity and plasticity constitute one of the most challenging areas of research due to the paucity of models to
study these cells' inherent complexity. Herein, we analyzed the role ofmonocytes/macrophages in glioma growth by
using a transgenic model that allows for conditional ablation of this cell population. We modeled glioma using
intracranial GL261-bearing CSF-1R–GFP+macrophage Fas-induced apoptosis (MAFIA) transgenicmice. Conditional
macrophage ablation was achieved by exposure to the dimerizer AP20187. Double immunofluorescence was used
to characterizeM1- andM2-likemonocytes/macrophages during tumor growth and after conditional ablation. During
glioma growth, the monocyte/macrophage population consisted predominantly of M2 macrophages. Conditional
temporal depletion of macrophages reduced the number of GFP+ cells, targeting mainly the repopulation of M2-
polarized cells, and altered the appearance of M1-like monocytes/macrophages, which suggested a shift in the M1/
M2 macrophage balance. Of interest, compared with control-treated mice, macrophage-depleted mice had a lower
tumor mitotic index, microvascular density, and reduced tumor growth. These results demonstrated the possibility
of studying in vivo the role and phenotype ofmacrophages in gliomas and suggested that transitory depletion of CSF-
1R+ population influences the reconstitutive phenotypic pool of these cells, ultimately suppressing tumor growth.
The MAFIA model provides a much needed advance in defining the role of macrophages in gliomas.
Neoplasia (2015) 17, 374–384Address all correspondence to: Candelaria Gomez-Manzano, MD, Departments of
Neuro-Oncology and Genetics, The University of Texas MD Anderson Cancer Center,
Houston, TX 77030, USA.
E-mail: cmanzano@mdanderson.org
1This study was supported by the National Institute of Health (R01 NS069964), the
Concern Foundation, the Rosalie B. Hite Fellowship, and the National Cancer
Institute Institutional Core grant (CA16672; Research Animal Support Facility at The
University of Texas MD Anderson Cancer).
2This article refers to supplementary materials, which are designated by Figures W1 to
W4 and are available online at www.neoplasia.com.
Received 21 October 2014; Revised 10 March 2015; Accepted 18 March 2015
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1476-5586/15
http://dx.doi.org/10.1016/j.neo.2015.03.003Introduction
Cells of the monocyte/macrophage lineage are considered key
components of the tumor microenvironment that operate in
conflicting ways as tumor-antagonizing or tumor-promoting inflam-
matory cells [1,2]. Thus, tumor-associated macrophages (TAMs) are
characterized by their diversity and plasticity, which can undergo two
polarization states that represent extremes of a continuum: the
classically activated M1 (proinflammatory) and the alternatively
activated M2-like (tumor promoting) phenotypes [3]. Studies of
several types of human solid tumors, including gliomas, have resulted
in controversial findings regarding the correlation of the presence of
TAMs and prognosis [4–7]. Functional studies aiming to deplete
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discrepancies and described macrophages as having either a positive or
a negative influence on tumor growth [8,9].
Modeling the tumor microenvironment is one of the most challenging
areas of research due to the paucity of models for studying its inherent
complexity. In this work, we took advantage of a previously generated
transgenic model that allows conditional and temporal ablation of the
macrophage population [10]. The macrophage Fas-induced apoptosis
(MAFIA) transgenic mouse model has been previously validated in
studies on the role of macrophages in bone marrow homeostasis [11–13]
and in several pathogenic diseases [14,15]. In this model, a murine c-fms
promoter induces the expression of a transgene containing enhanced
green fluorescent protein (EGFP) and a suicide fusion proteinmade up of
the FK506-binding protein and the cytoplasmic domain of Fas.
Expressed on cells of the mononuclear phagocyte system in the mouse,
c-fms encodes the receptor for macrophage colony-stimulating factor
(CSF-1) [16]. CSF-1R is known to be expressed in monocytes, tissue
macrophages, and monocyte-derived dendritic cells [17]. Specifically, in
the MAFIA brain tissue, EGFP is detectable in macrophages associated
with the microvasculature and meningeal surfaces and in microglia [16].
Systemic administration of AP20187 dimerizes the suicide protein,
inducing Fas-mediated apoptosis through activation of the caspase-8
pathway in myeloid lineage cells (i.e., macrophages and dendritic cells)
and ultimately reducing the number of EGFP+ cells bymore than 90% in
bone marrow and peritoneum and more than 70% in blood and in
spleen, lung, and thymus tissue [10]. The use of this model in cancer has
so far been limited to two recent studies on metastasis of B16-F10
melanoma [18] and in combination with a preneoplastic progression
model for breast cancer [19].
In this study, we analyzed the kinetics of intracranial syngeneic murine
GL261 cells by using the MAFIA mouse model to allow for easy
identification and conditional ablation of the tumor-associated myeloid
population. Our study unequivocally demonstrated the role of
CSFR-1R+ myeloid population in tumor proliferation, angiogenesis,
and growth at different stages of tumor development. In addition, we
show a switch in the M2/M1 polarization status that accompanies the
repopulation of TAMs on conditionalmyeloid ablation. Finally, the work
presented here sets up the basis for further studies on the pathobiology of
macrophages and drug testing for malignant glioma treatments.
Materials and Methods
Cell Culture and In Vitro Studies
Murine GL261 glioma cells and the RAW 264.7 macrophage cell line
were obtained from the Developmental Therapeutics Program (DTP),
Division ofCancerTreatment andDiagnosis (DCTD)TumorRepository
(National Institutes of Health (NIH), Frederick, MD) and American
Type Culture Collection (ATCC), Manassas, Virginia, respectively, and
cultured inDulbecco’s modified Eagle’s medium (Cellgro) with 10%FBS
(Cellgro) and antibiotics (50 U/ml penicillin and 50 μg/ml streptomycin)
in a humidified atmosphere of CO2/air (5%/95%) at 37°C.
For macrophage polarization, RAW 264.7 cells were cultured in
complete medium and stimulated for 24 hours with 1 ng/ml
lipopolysaccharides from Escherichia coli 055:B5 (Sigma, St. Louis,
Missouri) and 10 IU/ml Interferon gamma (IFN-γ) (Peprotech,
Rocky Hill, New Jersey) for M1 or 20 ng/ml Interleukin 4 (IL-4)
(R&D Systems, Minneapolis, Minnesota) for M2 activation.
GL261 and RAW 264.7 cell lines were treated with AP20187 with
different concentrations (0.01, 0.1, 1, and 10 nM) or vehicle for 24 or48 hours, and cell proliferation was measured using CyQUANT
Direct Cell Proliferation Assay Kit (Life Technologies, Grand Island,
New York) according the manufacturer’s protocol.
Real-Time Polymerase Chain Reaction Array
Total RNAwas extracted from RAW264.7 andM1- andM2-skewed
RAW 264.7 cells using mirVana miRNA Isolation Kit (Life Technol-
ogies). RNA (2 μg) was converted into cDNA using the High Capacity
RNA-to-cDNA Kit (Life Technologies), according to the manufacturer’s
instructions. The TaqMan Gene Expression Assay for murine arg1
(Mm00475988_m1), nos2 (Mm00440502_m1), and gapdh
(Mm99999915_g1) were purchased from Life Technologies. Quantita-
tive polymerase chain reaction (PCR) analysis was performed using the
Applied Biosystems 7500 Fast Real-Time PCRmachine. RelativemRNA
levels were quantified using the comparative cycle threshold (Ct) method
and the formula 2−ΔΔC t , with gapdh expression as the reference.
Flow Cytometry
Cells were washed with phosphate-buffered saline and incubated
with rat anti-mouse FCγIII/II receptor (CD16/CD32; clone 2.4G2;
BD Pharmingen, San Jose, California) antibody followed by APC
anti-mouse CD115/cFMS/CSF-1R antibody or matched IgG control
(Biolegend, San Diego, California). Before acquisition, cells were
stained with propidium iodide for gating of live cells. Analysis was
performed on 100,000 events collected per sample on Gallios
(Beckman Coulter, Brea, California) flow cytometer and analyzed
using FlowJo (Tree Star, Ashland, Oregon).
MAFIA Transgenic Mice
MAFIA transgenic mice (C57BL/6-Tg(Csf1r-EGFP-NGFR/
FKBP1A/TNFRSF6)2Bck/J) were purchased from The Jackson Labora-
tory, Bar Harbor, Maine. Offspring were screened by PCR on tail-snip
DNA taken at weaning using the Kapa Biosystems mouse genotyping kit,
as per the manufacturer’s instructions. GFP primers used for the analysis
were 5′-AAGTTCATCTGCACCACCG-3′ (forward) and 5′-TC
CTTGAAGAAGATGGTGCG-3′ (reverse). PCR thermal conditions
were set up according to the protocol provided byThe Jackson Laboratory.Animal Studies
GL261 glioma cells (2 ×104) were implanted (day 0 of the
experiment) in the right caudate nucleus of MAFIA mice using a
cannulated guide screw system as previously described [20], which
had been placed 14 days before. The B/B homodimerizer AP20187
was purchased from Clontech Laboratories, Mountain View,
California. Lyophilized AP20187 was dissolved in 100% ethanol at
a concentration of 62.5 mg/ml and stored at −20°C. For in vivo
experiments, treatment solutions were freshly prepared from a
dilution of 1.25 mg/ml (as recommended by Clontech Laboratories)
consisting of 4% ethanol, 10% PEG-400 (Sigma), and 2% Tween-20
(Fisher Scientific, Pittsburgh, Pennsylvania) in water. The volume of
solution was adjusted according to mouse body weight to deliver
5 mg/kg per mouse. AP20187 was injected intraperitoneally daily for
5 days, starting from either the first or the sixth day after glioma
implantation. Control animals were treated with vehicle solution
alone. Animals were sacrificed when indicated or when exhibiting
generalized or local symptoms of disease. Brains were removed,
photographed using a digital camera Nikon D60, fixed in 4%
formaldehyde for 24 hours at room temperature, and embedded in
paraffin. All animal studies were performed in the veterinary facilities
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TX) in accordance with institutional guidelines. The largest (a) and
the smallest (b) diameters of the tumors were measured, and tumor
volume was calculated using the formula: a × b2 × 0.4 [21].
Immunohistochemical and Immunofluorescence Analyses
Paraffin-embedded 5-μm-thick tissue sections were deparaffinized
and subjected to graded rehydration before staining. For double
immunofluorescence studies [Arginase 1 (Arg1)/GFP, inducible nitric
oxide (iNOS)/GFP, Iba1/GFP, CSF-1R/GFP], tissue sections were
subjected to heat-induced epitope retrieval (10 mM citrate buffer, pH
6.0) and blocked with 10% serum. Endogenous biotin and streptavidin
were blocked using Vector avidin/biotin and streptavidin/biotin kits
according to the manufacturer’s instructions. Overnight incubation at
4°C with antibodies against Arg1 V-20 (sc-18354; 1:1000; Santa Cruz
Biotechnology, Dallas, Texas), iNOS (ab15323; 1:1000; Abcam,
Cambridge, Massachusetts), Iba1 (MABN92; 1:1000; Millipore,
Billerica, Massachusetts), or CD31 antibody (AF3628, diluted 1:200,
R&D Systems) was performed. Bound antibodies were detected by
incubation with biotin-conjugated secondary antibody and DyLight
549 or DyLight 488 streptavidin (1:1000; Vector Laboratories,
Burlingame, California). Second primary antibodies [GFP
(NB600-308; 1:500; Novus Biologicals, Littleton, Colorado), GFP
I-16 (sc-5385; 1:100; Santa Cruz Biotechnology), and CSF-1R/cFMS
(sc-692; 1:200; Santa Cruz Biotechnology)] were incubated overnight
at 4°C and developed with Alexa Fluor 488– or Alexa Fluor 594–
conjugated secondary antibodies (1:1000; Invitrogen, Grand Island,
New York). Fluorescence-labeled slides were counterstained with
4′,6-diamidino-2-phenylindole (DAPI; Sigma), mounted with fluores-
cence mounting medium (Dako, Carpinteria, California), and
examined under a Zeiss Axiovert 200 M fluorescence microscope or a
confocal microscope (Olympus Fluoview FV1000).
For Ki67 immunohistochemical analysis, endogenous peroxidase
activity was quenched with 0.3% H2O2. Sections were blocked with
10% horse serum and a Vector avidin/biotin kit. Incubation with
Ki67 MM1 antibody (VP-K452; 1:100; Vector Laboratories) was
performed overnight at 4°C. Sections were then incubated with
biotinylated secondary antibody followed by peroxidase-conjugated
streptavidin (1:500; Beckman Coulter). The reaction was developed
using stable 3,3′-diaminobenzidine (DAB, Research Genetics,
Huntsville, Alabama). After immunoreaction, sections were counter-
stained with Harris hematoxylin and mounted with Cytoseal 60
(Thermo Scientific, Waltham, Massachusetts). Images were captured
using a bright-field microscope (Zeiss Axioskop 40).
For immunofluorescence and immunohistochemical analysis, 10
pictures were acquired randomly from central or peripheral areas of
tumors and, when indicated, from contralateral cerebral hemispheres
under ×20 or ×40 objectives. A minimum of three animals from each
experimental group was analyzed. The number of GFP+, Ki67+,
Arg1+/GFP+, and iNOS+/GFP+ cells was quantified in a double-
blind manner by two different researchers.
Quantification of Microvessel Density
Areas containing the most microvessels (or tumor “hot spots”) were
identified following immunostaining with anti-CD31 antibody.
Sections were examined with a fluorescence microscope at low
magnification (original magnification, ×40 and ×100), as previously
described [22]. Then, the individually stained microvessels in these
areas were counted at ×200 magnification over a square grid thatcorresponded to a field size of 0.16 mm2. Large microvessels and
single endothelial cells that were clearly separate from the microvessels
were included in the microvessel count; branching structures were
counted as one vessel, unless there was a break in the continuity of the
vessel, in which case it was counted as two distinct vessels. The mean
number of microvessels counted in five fields was used for analyses.
Statistical Analysis
Data are presented as mean ± SD. The P value for difference
between samples was calculated using double-sided Student’s t test.
P b .05 was considered statistically significant.
Results
Kinetics of GL261 Glioma Intracranial Growth and Tumor-
Associated Microglia/Macrophage Population in MAFIA
Transgenic Mice
To determine the kinetics of GL261 glioma growth in MAFIA
transgenic mice, we first analyzed tumor morphologic characteristics on
days 5, 10, 14, and 19 after tumor cell implantation (Figure 1A). We
performed hematoxylin and eosin (H&E) and Ki67 staining to assist in
the analysis of tumor morphology and tumor growth (Figure 1B). On
days 5 and 10 after tumor cell inoculation, GL261-derived tumors
exhibitedmultifocal distribution ofKi67+ cells in the area of injection of
the brain parenchyma. On day 14, the tumors were clearly established
and highly proliferative, with exponential growth. By day 19, the tumor
occupied almost the entire left hemisphere with slightly less cell density
that was due probably to the presence of dilated vascular structures. At
that time point, examination of the brain itself revealed secondary
effects to tumor mass pressure, such as midline shift and ventricular
compression. The tumor/normal brain edge was well defined, and no
significant signs of invasiveness were observed.
To identify the presence of tumor-associated microglia/macrophages
in MAFIA mice, we performed GFP immunofluorescence staining. As
early as 5 days after GL261 implantation, compared to the presence of
GFP+ cells in contralateral, non-tumor containing hemispheres, the
presence of GFP+ cells had increased (Figure 2A), which was suggestive
of activation/infiltration of myeloid cells into the tumor. Thus, in
tumor-free hemispheres, we detected relatively few microglia in the
resting stage, with thin branching processes, and small cell bodies
(Figure 2A). GL261-derived tumors analyzed 10 days after cell
implantation displayed microglia/macrophages with morphology
compatible with activation as demonstrated by their augmented cell
body size and amoeboid morphology. The density of GFP+ cells within
the tumor continued to increase, and by day 14 post-implantation, the
tumors harbored an even greater number of glioma-infiltrating
microglia/macrophages. Interestingly, the density of these GFP+ cells
decreased significantly from day 14 to day 19 (P b .001), associated to a
decreased cellularity due to the presence of necrotic areas as previously
reported [23], whereas the number of GFP+ cells (i.e., microglia/
macrophages) at the tumor periphery increased (P b .05; Figure 2, B
and C ). In sham-operated animals analyzed 5 and 10 days after mock
implantation (FigureW1A), we did not observe accumulation of GFP+
cells in the injection area, indicating that the recruitment or activation of
microglia/macrophages into the tumor was initiated by the presence of
glioma cells (Figure W1B).
To characterize the GFP+ population in the MAFIA model, we
analyzed the expression of Iba1 (which is highly expressed in cells of
the monocyte/macrophage lineage), and CSF-1R, by double
immunofluorescence. As expected, GFP and CSF-1R expression
Figure 1. Kinetics of GL261 intracranial glioma growth in MAFIA transgenic mice. (A) Scheme of the experiment. Briefly, MAFIA mice
underwent guided screw cannulation, and 14 days later, GL261 cells were implanted into the right caudate nucleus. Animals were
sacrificed 5, 10, 14, or 19 days after cell implantation, and their brains were assessed for morphologic characteristics. (B) Representative
images of H&E (left andmiddle columns) and Ki67 (right column) staining of GL261 intracranial glioma sections frommice sacrificed at the
indicated time points after tumor cell implantation. Scale bar, 500 μm (whole-brain tissue) or 50 μm (insets).
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show that, within the tumoral area, most Iba1+ cells (microglial) are
GFP+ (82.1 ± 1.46%). Of note, in normal brain, all Iba1+ cells were
GFP+ (Figure W2B). These data indicate that CSF-1R–expressing
cells encompass an important population, although not all monocyte/
macrophage lineage cells present in the glioma-bearing brain were
Iba1+, as previously found in other organs of this transgenic model
using F4/80 as a macrophage marker [10].
To further characterize the phenotype of the tumor-associated
microglia/macrophages, we analyze the expression of Arg1 (an M2
phenotype marker) and iNOS (an M1 phenotype marker) [24–26].
To this end, we performed double immunofluorescence staining for
GFP/Arg1 and GFP/iNOS expression in sections of brains of
GL261-bearing mice sacrificed at different times after cellimplantation. No Arg1+ cells were detected at day 5, but we
observed the presence of double-positive (GFP+/Arg1+) cells at day
10, which exhibited a more rounded morphology and cellular
processes compatible with early stages of microglia activation.
Quantification of the Arg1+/GFP+ cells at 14 and 19 days after
GL261cell implantation showed that 98 ± 1.5% of Arg1+ cells
expressed the GFP antigen, suggesting that Arg1 is expressed by
microglia/macrophages, and those exhibited an amoeboid morphol-
ogy suggestive of an activate cellular stage. In addition, we observed
that 50% to 75% of GFP+ cells expressed Arg1 and that the number
of M2-polarized microglia/macrophages at the tumor-normal brain
edge tended to increase during glioma growth (Figure 3, A and B). In
contrast, we did not detect iNOS+ cells in early stages of glioma
growth (days 5 and 10; Figure 3C ) or in tumor-normal edges at later
Figure 2.Microglia/macrophage accumulation in tumor-bearing hemisphere. (A) Representative images of GFP staining using fluorescent
microscopy show the presence of microglia/macrophages in tumor-bearing hemispheres, analyzed at the indicated time points after
GL261 cell implantation. Images of contralateral, non–tumor-bearing hemispheres are shown for comparison. Scale bar, 100 μm. Insets
show detailed cellular morphology. Scale bar, 60 μm. (B) Representative confocal microscopy images of GFP staining from the center and
periphery of tumors. Dashed line, approximate tumor (T)/normal brain (N) edge. Scale bar, 20 μm. (C) Quantification of GFP+ cells (×400)
present in the tumor area and in the tumor-normal brain edge area (periphery) on sections of brains from animals sacrificed on day 14 or
19 post-implantation. HPF, high-powered field. Data are presented as mean ± SD (n = 3 mice). *** P b .001 and * P b .05.
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cells expressing GFP in central tumor areas at late stages of tumor
development (days 14 and 19; Figure 3C ). These findings suggest
that M2-polarized glioma-associated macrophages constitute the
predominant population in GL261-derived intracranial gliomas. Of
interest, most of the Arg1+ cells expressed GFP and approximately
70% of iNOS-positive cells in the whole tumor area expressed the
fluorescent protein (72 ± 12.8%). These data suggest that
M2-polarized macrophages constitute the major CSF-1R+ popula-
tion, in agreement with our in vitro polarization studies (Figure W3)
and a recent report that examined human macrophages [27].
Ablation of Macrophages in the MAFIA Model Impairs Inflow
of Myeloid Cells into the Tumor and Promotes Skew Toward
the M1 Phenotype
To understand the role of microglia/macrophages in glioma
development, we targeted this population by administering for fiveconsecutive days (1-5 days or 6-10 days) after cell implantation the
B/B homodimerizer drug AP20187 to mice bearing GL261
intracranial tumors (Figure W4A). As mentioned previously,
AP20187 induces Fas-mediated apoptosis through activation of the
caspase-8 pathway in myeloid lineage cells. The day after treatment
was completed (day 6 for group A and day 11 for group B), brains
were analyzed for GFP+ cells. In tumor-containing hemispheres, the
GFP+ cells were forcefully depleted (Figure W4B). The presence of
GFP+ cells in the contralateral, non–tumor-containing hemisphere
was not affected by the treatment (data not shown). Our data
suggested that normal microglia is not targeted by AP20187, which is
consistent with previous reports showing the inability of this drug
dimerization to cross the blood-brain barrier [10,28].
To analyze the long-term impact of pharmacological targeting of
the macrophage/microglia population in glioma tumors, we allowed
for full glioma development in both group A and group B of the
experiment (Figure 4A). Control animals were sacrificed between 16
Figure 3. Phenotypic characterization of the glioma-associated microglia/macrophage population. (A) Representative confocal images of
Arg1 (red) and GFP (green) staining in brain sections from GL261 glioma–bearing animals sacrificed on day 5, 10, or 14 post-implantation.
(Inset)White arrows highlight the increase in the number of Arg1+/GFP+ cells and change inmorphology over time. DAPI (blue) was used for
cellular nuclear staining. Scale bar, 20 μm. (B) Quantification of Arg1+/GFP+ cells in the center and periphery of tumors frommice sacrificed
on day 14 or 19. Data are presented as mean ± SD (n = 3 mice). (C) Representative confocal images of iNOS (red) and GFP (green
fluorescence) staining of brains of tumor-bearing mice sacrificed at the indicated times. (Inset) White arrows highlight the rare iNOS+/GFP+
cells, which were observed only at day 14. DAPI (blue) was used for nuclear staining. Scale bar, 20 μm.
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evident. Although AP20187-treated animals did not show signs
compatible with glioma progression, we decided, on this time period,
to have a more accurate comparison of tumor growth and analysis of
the macrophage population. Analysis of the brains of the
AP20187-treated animals revealed fewer GFP+ cells within tumors.
We found that early ablation of macrophage cells (1-5 dayspost-implantation) resulted in an approximately 50% reduction in
the number of GFP+ cells in tumors (P b .01 vs control), while
postponed treatment (6-10 days post-implantation) diminished the
accumulation of GFP+ cells in tumors by 65% (P b .001 vs control;
Figure 4, B and C ). Moreover, we found significantly fewer
microglia/macrophages infiltrating the tumor periphery (by ~60%)
in both early and postponed myeloid cell ablation (control vs
Figure 4. Influence of conditional macrophage ablation on tumor-associated myeloid cell reconstitution. (A) Scheme of the experiment.
Briefly, GL261 cells were implanted into the right caudate nucleus of MAFIAmice. AP20187 or vehicle was administered daily from days 1
to 5 (group A) or from days 6 to 10 (group B) of the experiment. Animals were sacrificed 16 to 21 days after cell implantation. (B) Tumor
sections from vehicle- or AP20187-treated mice were stained for GFP expression. Representative images from the center (upper row) and
periphery (lower row) of tumors were acquired using confocal microscopy. Dashed line, approximate tumor (T)/normal brain tissue (N)
edge. DAPI was used as nuclear staining. Scale bar, 20 μm. (C) Number of GFP+ cells per HPF (×400). Data are presented as mean ± SD
(n = 3 mice). *** P b .001, ** P b .01, and * P b .05.
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P b .01). Ablation had no notable effect on microglia in intact brain,
including the contralateral hemisphere.
To determine the impact of the temporal ablation of microglia/
macrophages on the reconstitution of the tumor-associated
myeloid population phenotype, we used double immunofluores-
cence to analyze the M1 and M2 status of those cells. Confocal
analysis of Arg1+ and GFP+ cells in control mice showed that both
early (1-5 days) and postponed (6-10 days) injection of the
dimerization agent AP20187 reduced the number of double
positive, Arg1+GFP+ cells in the center and periphery of the tumor
(P b .01 and P b .001, respectively; Figure 5A). These resultssuggested that the number of M2-like polarized cells in the
reconstituted pool decreased.
We then analyzed the M1 polarization of the reconstituted pool by
performing double immunofluorescence image for GFP and iNOS.
As we expected, iNOS+ cells within the tumor of control-treated
MAFIA mice were rarely detected and appeared to be randomly
distributed. Interestingly, agglomerations of iNOS+GFP+ cells were
observed in tumor central areas in mice in which myeloid cell ablation
was performed (Figure 5B). Compared with mice treated
with AP20187 on days 1 to 5 and days 6 to 10, the number of
iNOS+GFP+ cells in control-treated mice was approximately
seven-fold and two-fold higher, respectively.
Figure 5. Modifications in the repopulation of M1/M2-polarized myeloid cells after macrophage ablation. (A) Representative images of
double immunofluorescence analysis for the expression of Arg1 (red) and GFP (green) in GL261-derived tumors of vehicle- or
AP20187-treated MAFIA mice. DAPI (blue) was used for nuclear staining. Curved dashed lines indicate the approximate tumor (T)/normal
brain (N) edge. Scale bar, 20 μm. The graph shows the number of double positive Arg1+GFP+ cells per HPF (×400; central and peripheral
areas). Data are presented as mean ± SD (n = 3 mice). (B) Representative images of sections from tumor-bearing mice treated with
vehicle solution or AP20187 that were stained for iNOS and GFP expression. (Insets) Arrows point to iNOS+GFP+ cells. Scale bar, 20 μm.
Quantitative analysis of the number of double positive iNOS+GFP+ cells per HPF in GL261-derived intracranial tumors from control or
AP20187-treated mice (central areas). Data are presented as mean ± SD (n= 3mice). (C) Quantitative analysis of M1 ratio as the/M1 ratio
as the number of double positive Arg1+GFP+ cells per HPF versus the number of double positive iNOS+GFP+ cells per HPF in
GL261-derived intracranial tumors fromcontrol orAP20187-treatedmice (central areas). ****Pb .0001, ***Pb .001, **Pb .01, and *Pb 0.05.
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of the reconstituted myeloid population present in the glioma
microenvironment of MAFIA mice. Specifically, the M2/M1 ratio on
reconstitution decreased by nine-fold and three-fold in mice treatedwith AP20187 on days 1 to 5 and days 6 to 10, respectively
(Figure 5C; P b .0001 and P b .01, respectively).
Taken together, our results suggested that ablation of the CSF-1R+
myeloid population substantially alters the relative M1 and M2
382 Macrophage Ablation Reduces M2-Like Populations Gabrusiewicz et al. Neoplasia Vol. 17, No. 4, 2015representation in the tumor microenvironment and, subsequently,
the functionality of the macrophage/microglia population.
Myeloid Cell Ablation Strongly Impairs the Growth of
Intracranial Glioma
To further explore the effect of temporal ablation of the tumor-infil-
trating myeloid cells (CSF-1R–GFP+ cells) on glioma growth, weFigure 6. Outcome of temporal macrophage ablation on tumor growt
photos of whole brains and coronal sections. Numbers (1-8) represen
and AP20187-treated mice (n = 6 mice in control-treated group and
mean ± SD. * P b .05. (C) Representative H&E-stained sections from
cells in tumors from control-treated and AP20187-treated MAFIA m
scored from three or four microscopic fields (×200). * P b .05. (Right
Ki67+ cells (brown; nuclear staining) in both control- and AP20187
microvessel density in tumors from control-treated and AP20187-trea
microvessel density scored from three or four microscopic fields (×
showing vascular structures (CD31+, red fluorescence) in both contro
nuclear staining. Scale bar, 50 μm.analyzed the phenotype of the tumors of MAFIA mice treated with
AP20187 and compared it with tumors in control-treated mice
(Figure 4A). Tumor volume analysis revealed that microglia/macro-
phage-depleted mice had smaller tumors, approximately 50% in size,
than those of vehicle-treated animals (Figure 6,A–C, control vs AP20187
on days 1-5d and on days 6-10;P b .05 for both comparisons), suggesting
that microglia/macrophage ablation resulted in decreased tumor growth.h. Design of experiment is described in Figure 4A. (A) Macroscopic
t individual tumor-bearing mice. (B) Tumor volume in control-treated
n = 3 mice in each AP20187-treated group). Data are presented as
each experimental group. Scale bar, 500 μm. (D) Number of Ki67+
ice. (Left panel) Data are presented as mean ± SD of Ki67+ cells
panel) Representative microscopic pictures showing distribution of
(days 1-5)-treated animals. Scale bar, 50 μm. (E) Quantification of
ted MAFIA mice. (Left panel) Data are presented as mean ± SD of
200). * P b .05. (Right panel) Representative microscopic pictures
l- and AP20187 (days 1-5)-treated animals. DAPI (blue) was used for
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cells on tumor proliferation, we measured the number of Ki67+ cells
within tumors. This analysis revealed a decrease of approximately 50% in
the mitotic index when AP20187 was started immediately after tumor
implantation (days 1-5, P b .05) or after 6 days (P = .0562; Figure 6D).
Of note, AP20187 treatment (ranging 0.01 to 10 nM) did not affect
GL261 glioma cells or genetically wild-type RAW 264.7 macrophages as
assessed by an in vitro viability assay (data not shown), suggesting that the
treatment did not affect unexpected target populations. In addition,
temporary ablation of CSF-1R–GFP+ cells resulted in decreased
microvascular density after both AP20187 treatment regimens (P b
.05; Figure 6E). Together, our results showed that temporal ablation of
myeloid populations resulted in decrease of the tumor proliferative and
angiogenic properties, affecting significantly tumor growth.
Discussion
Here, we report that conditional and temporal ablation of the CSF-1R+
population affect the reconstituted glioma myeloid population.
Specifically, such ablation results in an increased M1/M2 ratio that,
in turn, was associated with decreased tumor mitotic index,
angiogenesis, and growth. Furthermore, we validated the use of the
MAFIA transgenic model for further preclinical studies of brain tumors.
We found that the kinetics of the GL261 intracranial glioma
growth in this transgenic model were similar to those previously
described for other models [29–31]. Of interest, we observed an
initial adaptive phase characterized by small islets of tumor cells
scattered around the injection site, with exponential tumor growth
after day 10 after tumor cell implantation. Consistent with other
studies [22,27,32], GL261 intracranial glioma was characterized by
tumoral microglia/macrophage infiltration, which was easily identi-
fied in the MAFIA model as accumulation of easily GFP-trackable
cells. Our study also provided evidence of an increased presence of a
microglia/macrophage population, which underwent morphologic
modifications in the tumoral area during the adaptive tumoral phase,
suggestive of a shift from a resting to an active state.
To further study the tumor infiltrating microglia/macrophage
population, we performed immunofluorescence analysis to discriminate
between the classically activated M1 and the alternatively activated
M2 microglia/macrophage phenotype [3,33,34]. Although glioma-
infiltrating GFP+ microglia/macrophages were evident within 5 days
after cell implantation, they did not express detectable levels of the M2
marker Arg1 [24–26] until late in the adaptation stage. Furthermore,
the accumulation of Arg1+ cells increased over time to represent the
largest GFP+ microglia/macrophage population within 14 days after cell
implantation. However, GFP+ cells rarely colocalized with the M1
marker iNOS [24–26], which confirmed a predominantM2phenotype
or protumorigenic phenotype of the microglia/macrophages associated
with the GL261 glioma model [32].
Our data showed that conditional temporal ablation of microglia/
macrophages was successfully achieved using the MAFIA transgenic
model. Other pharmacological ablation methodologies, such as
clodronate liposomes, are less selective in that they deplete cells
depending on their phagocytic properties, including subtypes of
T cells, and might fail to target other cells of peripheral macrophage
lineage that eventually would be recruited as TAMs [10,14,28]. Of
note, in the MAFIA transgenic model, ablation of normal CSF-1R+
microglia in the contralateral, non–tumor-bearing hemisphere was
not noted, probably because of the inability of the dimerization
treatment to cross the intact blood-brain barrier [10,14,23,28].Interestingly, we found that conditional ablation, although
transient, significantly affected the number and phenotype of the
reconstituted pool of tumor-associated myeloid cells, which reduced
the presence of GFP+ cells in tumors by 40% to 80%. Furthermore,
the infiltrating population switched the polarization status due to a
decrease in the M2 population. The presence of M2-polarized
microglia/macrophages positively correlates with malignancy in
gliomas; therefore, modifying the landscape scenario toward a more
M1-like phenotype may be a useful strategy for glioblastoma therapy.
Our results are in line with other efforts to neutralize tumor-
associated chronic inflammation, such as blocking the nuclear factor
kappa-light-chain-enhancer of activated B cells (NFκB) or signal
transducer and activator of transcription 3/6 (STAT3/6) pathway or
inhibiting cytokine pathways that dictate the recruitment or immune
cell function, such as CSF-1 or chemokine (C-C motif) ligand 2
(CCL2) [34,35].
The work presented here demonstrated that temporal ablation of the
macrophage population is sufficient to achieve a significant anti-glioma
effect. The role of M2-polarized macrophages in promoting angiogen-
esis, cell migration and invasion, and an immunosuppressive tumor
environment might explain that the decrease in number of GFP+ cells
and M2/M1 ratio in the reconstituted population resulted in a decrease
in tumor growth, angiogenesis, and proliferation in the model here
studied [3]. Importantly, the MAFIA transgenic model is designed to
both detect and target cells that express CSF-1R. This offers an
interesting parallelism with recent studies that showed the CSF-1R
inhibitor, BLZ945, resulted in both decreasedM2macrophagemarkers
and subsequent tumor growth in a proneural glioma model [36].
Similarly, studies in other types of cancers using a monoclonal antibody
that inhibits CSF-1R activation, RG7155, resulted in preferential
targeting of the M2-polarized populations [27] and a subsequent
increase in CD8+ T cell population [35] and decrease in FoxP3+ T
regulatory cells [27].
In conclusion, we demonstrated that temporal ablation of
macrophages in the MAFIA model results in an M2-to-M1 shift in
the reconstituted myeloid population, which decreased tumor
proliferation, angiogenesis, and growth. In addition, the intracranial
glioma MAFIA transgenic model is an interesting tool for examining
the putative role of macrophages in therapy resistance and for
modeling the effect of new drugs targeting macrophages, either as
single agents or in combination with glioma-targeted therapies.
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